Silexion Therapeutics Corp filed a Form S-1 registration statement for an initial public offering on 2024-09-10. It has amended it 4 times. It filed its final prospectus on 2026-08-13. Each fact below is quoted from the filing named with it.
What the filings say
Shares offered
We are offering 2,028,619 ordinary shares (the “shares”), par value $0.135 per share of Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion”, the “Company”, “our company”, “we” or “us”), together with 3,846,161 ordinary warrants (the “ordinary warrants”), to purchase 3,846,161 ordinary shares at the public offering price of $0.65 per share and ordinary warrant pursuant to this prospectus.From the 424B4 filed 2026-08-13
Use of proceeds
We currently intend to use the net proceeds from this offering to advance our pre-clinical and clinical studies, and for general corporate purposes.From the 424B4 filed 2026-08-13
Net loss or income
We have incurred net losses since our inception in November 2008, including net losses of $2.7 million and $1.7 million for the three months ended March 31, 2026 and 2025, respectively, and $11.9 million for the year ended December 31, 2025.From the S-1/A filed 2026-08-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-10 | Registration statement filed | S-1 |
| 2024-10-09 | Registration statement filed | S-1 |
| 2024-10-31 | Registration statement filed | S-1 |
| 2025-01-14 | Registration statement amended | S-1/A |
| 2025-01-14 | Registration statement amended | S-1/A |
| 2025-01-17 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-02-12 | Registration statement filed | S-1 |
| 2025-03-27 | Registration statement amended | S-1/A |
| 2025-08-26 | Registration statement filed | S-1 |
| 2025-09-05 | Registration statement filed | S-1 |
| 2025-09-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-08-07 | Registration statement filed | S-1 |
| 2026-08-10 | Registration statement amended | S-1/A |
| 2026-08-13 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Silexion Therapeutics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.